The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of erlotinib after gefitinib failure in advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS): A matched-pair case-control study.
M. Huang
No relevant relationships to disclose
D. Luo
No relevant relationships to disclose
X. Zhang
No relevant relationships to disclose
M. Yu
No relevant relationships to disclose
B. Zou
No relevant relationships to disclose
Y. Li
No relevant relationships to disclose
J. Long
No relevant relationships to disclose
J. Wang
No relevant relationships to disclose
F. Peng
No relevant relationships to disclose
Y. Xu
No relevant relationships to disclose
L. Li
No relevant relationships to disclose
L. Ren
No relevant relationships to disclose
M. Hou
No relevant relationships to disclose
Y. Lu
No relevant relationships to disclose